ArticleFrontiers in genetics2026
Charting the immune terrain: a novel risk model for thyroid cancer prognosis.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To construct a prognostic risk model for thyroid cancer based on immune genes and analyze the correlation between immune genes and immune infiltration. Methods: A retrospective study was conducted on 180 patients with thyroid cancer treated in our hospital during May 2022 to April 2025. Based on the prognosis, the subjects were graded as good prognosis group of 126 cases and poor prognosis group of 54 cases. The influencing factors were analyzed by a binary logistic regression model, receiver operating characteristic curve and goodness of fit test. Single sample gene set enrichment analysis was used to perform immune infiltration analysis on the expression matrix of peripheral blood mononuclear cells. The GSEA algorithm was used to calculate the abundance of tumor associated immune cell infiltration. Pearson correlation analysis was used to investigate the correlation. The TCGA-THCA database was used to analyze the differential expression of genes, as well as the correlation with clinical pathological features. Results: The expression levels of CDK1, B3GNT7, S100A9, and MMP9 genes were higher in the poor prognosis group than the good prognosis group ( Conclusion: CDK1, B3GNT7, S100A9, and MMP9 were independent risk factors for poor prognosis in thyroid cancer. The prognostic prediction model may provide objective evidence for early screening of high-risk cases in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.